Separate indirect from direct design evidence (SIDDE)

Fixed effects model: 

               comparison k  nma direct indir. RoR z p-value
 daridorexant:eszopiclone 0 0.29      .   0.29   . .       .
 daridorexant:lemborexant 0 0.35      .   0.35   . .       .
     daridorexant:placebo 2 0.55   0.55      .   . .       .
   daridorexant:ramelteon 0 0.70      .   0.70   . .       .
    daridorexant:zolpidem 0 0.30      .   0.30   . .       .
  eszopiclone:lemborexant 0 1.19      .   1.19   . .       .
      eszopiclone:placebo 1 1.90   1.90      .   . .       .
    eszopiclone:ramelteon 0 2.44      .   2.44   . .       .
     eszopiclone:zolpidem 0 1.02      .   1.02   . .       .
      lemborexant:placebo 1 1.60   1.60      .   . .       .
    lemborexant:ramelteon 0 2.04      .   2.04   . .       .
     lemborexant:zolpidem 0 0.86      .   0.86   . .       .
        ramelteon:placebo 1 0.78   0.78      .   . .       .
         zolpidem:placebo 1 1.86   1.86      .   . .       .
       ramelteon:zolpidem 0 0.42      .   0.42   . .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
[1] "Percent of comparisons where there is some evidence (p-value<0.05) of disagreement between direct and indirect sources: NaN. (0 out of 0 comparisons)."
[1] "File created on 2022-01-30"
